Skeletal myoblasts offer an easily expandable source of autologous myogenic cells for cardiac repair. Despite their remarkable potential and the encouraging results emanating from their use in animal studies and human phase-1 trials, there are fundamental issues confronting the development of this approach to achieve better prognosis. This includes optimization of transplantation conditions, the immunobiology and mechanism of donor cell survival after transplantation, the underlying mechanism of their contribution towards improved cardiac function and effectiveness of combo-therapy involving myoblast transplantation with multiple angiogenic gene delivery using non-viral vector transfection. Our fundamental hypothesis is that primary skeletal myoblasts are conditionally immunoprivileged when transplanted across the histocompatibility barriers. Clonal selection of sub-populations of primary myoblasts may help to identify their immunological behavior. The fusion competent donor myoblast having a complete set of normally functioning genes, undergo fusion with the ischemically damaged host cardiomyocytes, compensate for their lost genes and form mosaic muscle fibers which contribute towards the improved cardiac performance. Moreover, angiogenic synergy through multiple angiogenic growth factor genes administration, together with myoblast transplantation may help to enhance the survival of donor skeletal myoblasts together with angiomyogenesis for cardiac repair. These hypotheses will be tested in well-established rat and porcine heart models of myocardial infarction, using a multidisciplinary approach including physiology, biochemistry, molecular biology, immunohistochemistry, and gene therapy.
The specific aims of our proposal are:
Aim -1) to characterize in vitro and define the in vivo behavior of human skeletal myoblast post transplantation in an animal model of myocardial infarction and develop strategies to elucidate the mechanism of the donor myoblast survival and define the immunologic basis of myoblast transplantation for cardiac repair. The results of these studies will pave the way for the use of myoblast from allogenic source and overcome the logistic problems associated with the use of autologous myoblast.
Aim -2 to study the exact mechanism of improvement in the cardiac function after myoblast transplantation therapy.
Aim -3 to define and optimize the transplantation conditions with respect to cell number, number of sites to be injected, optimum time for cell transplantation after the onset of infarction episode, and the preferential route of administration to achieve optimum prognosis.
Aim -4 to transfect skeletal myoblasts with multiple angiogenic growth factor genes to achieve angiogenic synergy between various growth factors and myoblast therapy for cardiac repair. We believe that the findings of this proposal may eventually lead to achieve better prognosis from skeletal myoblast transplantation in the clinical perspective.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL080686-01
Application #
6916046
Study Section
Vascular Cell and Molecular Biology Study Section (VCMB)
Program Officer
Liang, Isabella Y
Project Start
2005-04-18
Project End
2010-03-31
Budget Start
2005-04-18
Budget End
2006-03-31
Support Year
1
Fiscal Year
2005
Total Cost
$525,820
Indirect Cost
Name
University of Cincinnati
Department
Pathology
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Buccini, Stephanie; Haider, Khawaja Husnain; Ahmed, Rafeeq P H et al. (2012) Cardiac progenitors derived from reprogrammed mesenchymal stem cells contribute to angiomyogenic repair of the infarcted heart. Basic Res Cardiol 107:301
Pasha, Zeeshan; Haider, Husnain Kh; Ashraf, Muhammad (2011) Efficient non-viral reprogramming of myoblasts to stemness with a single small molecule to generate cardiac progenitor cells. PLoS One 6:e23667
Takamiya, Michitaka; Haider, Khawaja H; Ashraf, Muhammad (2011) Identification and characterization of a novel multipotent sub-population of Sca-1? cardiac progenitor cells for myocardial regeneration. PLoS One 6:e25265
Ahmed, Rafeeq P H; Haider, Husnain K; Buccini, Stephanie et al. (2011) Reprogramming of skeletal myoblasts for induction of pluripotency for tumor-free cardiomyogenesis in the infarcted heart. Circ Res 109:60-70
Ahmed, Rafeeq P H; Ashraf, Muhammad; Buccini, Stephanie et al. (2011) Cardiac tumorigenic potential of induced pluripotent stem cells in an immunocompetent host with myocardial infarction. Regen Med 6:171-8
Afzal, Muhammad R; Haider, Husnain Kh; Idris, Niagara Muhammad et al. (2010) Preconditioning promotes survival and angiomyogenic potential of mesenchymal stem cells in the infarcted heart via NF-kappaB signaling. Antioxid Redox Signal 12:693-702
Durrani, Shazia; Konoplyannikov, Mikhail; Ashraf, Muhammad et al. (2010) Skeletal myoblasts for cardiac repair. Regen Med 5:919-32
Ahmed, Rafeeq P H; Haider, Khawaja Husnain; Shujia, Jiang et al. (2010) Sonic Hedgehog gene delivery to the rodent heart promotes angiogenesis via iNOS/netrin-1/PKC pathway. PLoS One 5:e8576
Huang, Wei; Zhang, Dongsheng; Millard, Ronald W et al. (2010) Gene manipulated peritoneal cell patch repairs infarcted myocardium. J Mol Cell Cardiol 48:702-12
Kim, Ha Won; Haider, Husnain K; Jiang, Shujia et al. (2009) Ischemic preconditioning augments survival of stem cells via miR-210 expression by targeting caspase-8-associated protein 2. J Biol Chem 284:33161-8

Showing the most recent 10 out of 32 publications